资源描述：
《Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer.PDF》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、AnticancerOriginalResearchPaperAnalysisoftwotopotecantreatmentschedulesinpatientswithrecurrentovariancancerIlanBruchim1,2,ZipiBen-Harim1,2,EttiePiura1,2,GabiHaran1,2,AmiFishman1,21DivisionofGynecologicOncology,MeirMedicalCenter,KfarSaba,Israel,2SacklerSchoolofMedicine,TelAvivUniversity,T
2、elAviv,IsraelTwotopotecantreatmentschedulesinpatientswithrecurrentepithelialovariancancerwereevaluated.ProtocolA(21 days)was1.5 mg/m2/daytopotecanondays1through5ofa21-daycycle;ProtocolB(weekly)4 mg/m2ondays1,8,and15ofa28-daycycle.Efficacywasdeterminedbyclinicalexam,CTscan,andCA125levels.
3、Forty-threepatientsonProtocolAand21onProtocolBwereevaluated.Assecond-linetreatment,ProtocolAresponsewas9/20(45%).ResponsetoProtocolBwas4/17(23.5%;NS).Asthirdlineormore,theresponseonProtocolsAandBtogetherwasonly3/27(11%).High-gradehaematologicaltoxicitywasreportedin12/43(27.9%)onProtocolA
4、and1/21(4.8%)onProtocolB(p = 0.04).Therewasnodifferenceinprogression-free-intervalsbetweenschedulesinsecond-linetreatment.Theweeklyprotocolhadlowerseverehaematologicaltoxicity.Clinicalresponseinthirdlineormorewasverylow.Keywords:Epithelialovariancancer,Chemotherapy,TopotecanIntroductionT
5、opotecan(Hycamtin®;GlaxoSmithKline,Philadelphia,Epithelialovariancancer(EOC)isthemostlethalgynae-PA,USA)asemi-syntheticanalogueofcamptothecin,cologicmalignancy,representingthefifthleadingcauseisaspecifictopoisomeraseI-inhibitor6thatcausessin-ofcancerdeathinwomenintheUnitedStates.1In2008,
6、gle-strandbreaksindeoxyribonucleicacidduringrepli-ovariancancerwastheseventhmostcommoncancerincation.7Ithasanti-tumouractivityagainstseveralsolidwomenworldwideandincidencerateswerehighestintumoursandhasshownanti-tumouractivityinbothdevelopedcountries.2Seventy-fivepercentofpatientsplatinu
7、m-sensitiveandplatinum-resistantrelapsedEOCwithovariancancerarediagnosedatanadvancedstagewithgenerallyhigherresponseratesinpatientswithplat-ofdisease.Thecombinationofaggressivesurgicaldebulk-inum-sensitivetumours.8ingandchemotherapyhasincreasedtheoveralllifespanThedose-li
